| abstract |
The present invention provides compounds for use in a method for treatment of hepatitis C, wherein the compound binds to the inactive conformational state of the Zn+2-free NS3 protease of the hepatitis C virus (HCV), stabilizing said conformation, and therefore preventing the activating effect of the interaction with the two cofactors, Zn+2 and NS4A, and, thus, effectively inhibiting allosterically the catalytic activity of the protease. |